Eribulin affected pathways | p values (-log) | Paclitaxel affected pathways | p values (-log) |
---|---|---|---|
Cell cycle control of chromosomal replication | 6.85E+00 | PI3K/AKT signaling | 5.91E+00 |
Granzyme A signaling* | 6.27E+00 | Hepatic fibrosis/hepatic stellate cell activation* | 4.59E+00 |
RAN signaling | 3.37E+00 | NRF2-mediated oxidative stress response | 4.11E+00 |
Polyamine regulation in colon cancer | 3.03E+00 | Glucocorticoid receptor signaling | 4.07E+00 |
Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis* | 2.79E+00 | Aryl hydrocarbon receptor signaling | 3.89E+00 |
Airway pathology in chronic obstructive pulmonary disease | 2.68E+00 | IGF-1 signaling | 3.82E+00 |
IL-17A signaling in fibroblasts* | 2.44E+00 | p53 signaling | 3.79E+00 |
Hepatic fibrosis/hepatic stellate cell activation* | 2.10E+00 | Granzyme A signaling* | 3.30E+00 |
Bladder cancer signaling* | 2.09E+00 | Cell cycle regulation by BTG family proteins | 3.19E+00 |
Mismatch repair in eukaryotes | 2.06E+00 | Aldosterone signaling in epithelial cells | 2.95E+00 |
Putrescine degradation III | 2.01E+00 | MIF regulation of innate immunity | 2.87E+00 |
 |  | CDK5 signaling | 2.70E+00 |
 |  | Wnt/b-catenin signaling | 2.60E+00 |
 |  | Role of macrophages, fibroblasts and endothelial cells in Rrheumatoid arthritis* | 2.42E+00 |
 |  | HGF signaling | 2.38E+00 |
 |  | MIF-mediated glucocorticoid regulation | 2.38E+00 |
 |  | Estrogen receptor signaling | 2.37E+00 |
 |  | Role of IL-17A in arthritis | 2.34E+00 |
 |  | VDR/RXR activation | 2.31E+00 |
 |  | Role of CHK proteins in cell cycle checkpoint control | 2.30E+00 |
 |  | IL-17A signaling in fibroblasts* | 2.28E+00 |
 |  | Stearate biosynthesis I (animals) | 2.28E+00 |
 |  | Superoxide radicals degradation | 2.24E+00 |
 |  | Apoptosis signaling | 2.06E+00 |
 |  | CD40 signaling | 2.06E+00 |
 |  | Bladder cancer signaling* | 2.03E+00 |
 |  | Melanoma signaling | 2.00E+00 |